{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Backfill&page=2", "query": { "intervention": "Backfill", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Backfill&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-05T13:28:33.000Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05870579", "title": "[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "[68Ga]Ga-NeoB", "type": "DRUG" }, { "name": "[177Lu]Lu-NeoB", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Goserelin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 28, "start_date": "2023-11-13", "completion_date": "2032-04-27", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-05T13:28:33.000Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05870579" }, { "nct_id": "NCT07335497", "title": "CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced / Metastatic Solid Tumors" ], "interventions": [ { "name": "CR-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crescent Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2026-02-17", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-05T13:28:33.000Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07335497" }, { "nct_id": "NCT05519449", "title": "Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Metastatic Castration-resistant Prostate Cancer", "Castration Resistant Prostatic Cancer" ], "interventions": [ { "name": "JANX007", "type": "BIOLOGICAL" }, { "name": "Darolutamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janux Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 272, "start_date": "2022-09-15", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-05T13:28:33.000Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05519449" }, { "nct_id": "NCT07121946", "title": "This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma Refractory/ Relapsed", "DLBCL - Diffuse Large B Cell Lymphoma", "Mantle Cell Lymphoma (MCL)", "Follicular Lymphoma ( FL)", "Marginal Zone Lymphoma (MZL)" ], "interventions": [ { "name": "LTZ-301", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "LTZ Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-01-29", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-05T13:28:33.000Z", "location_count": 6, "location_summary": "Duarte, California • St Louis, Missouri • Buffalo, New York + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07121946" }, { "nct_id": "NCT06179511", "title": "Study of AZD9829 in CD123+ Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematological Malignancies" ], "interventions": [ { "name": "AZD9829", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2024-01-31", "completion_date": "2026-02-24", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-05T13:28:33.000Z", "location_count": 7, "location_summary": "Duarte, California • St Louis, Missouri • New York, New York + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06179511" }, { "nct_id": "NCT05364073", "title": "Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)", "Metastatic Non-Small Cell Lung Cancer", "Advanced Non-Small Cell Lung Cancer", "HER2 Exon 20 Mutations", "EGFR Exon 20 Mutations", "EGFR Uncommon Mutations, Including G719X and S768I" ], "interventions": [ { "name": "Furmonertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArriVent BioPharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2022-06-30", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-09-05T13:28:33.000Z", "location_count": 7, "location_summary": "Prescott, Arizona • Sacramento, California • Whittier, California + 4 more", "locations": [ { "city": "Prescott", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Celebration", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05364073" }, { "nct_id": "NCT06737393", "title": "Postoperative Bladder Filling After Outpatient Laparoscopic Hysterectomy and Time to Discharge", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Patient Discharge", "Urinary Complication" ], "interventions": [ { "name": "Backfill", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Tennessee", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 112, "start_date": "2025-01-01", "completion_date": "2026-01-01", "has_results": false, "last_update_posted_date": "2024-12-17", "last_synced_at": "2026-09-05T13:28:33.000Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06737393" }, { "nct_id": "NCT06759649", "title": "A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm", "Cancer, Malignant Tumors" ], "interventions": [ { "name": "COM503", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Compugen Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-01-07", "completion_date": "2027-11-22", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-05T13:28:33.000Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Grand Rapids, Michigan + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06759649" }, { "nct_id": "NCT03141372", "title": "Urinary Retention After Total Laparoscopic Hysterectomy With Immediate Foley Catheter Removal Versus Backfill Void Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Urinary Retention", "Voiding Disorders" ], "interventions": [ { "name": "Void Trial using Foley catheter", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Sara Farag", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 84, "start_date": "2017-05-16", "completion_date": "2018-04-30", "has_results": true, "last_update_posted_date": "2018-10-11", "last_synced_at": "2026-09-05T13:28:33.000Z", "location_count": 1, "location_summary": "Weston, Florida", "locations": [ { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03141372" }, { "nct_id": "NCT07700160", "title": "First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "VBC108", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VelaVigo Bio Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2026-07-30", "completion_date": "2029-09-17", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-05T13:28:33.000Z", "location_count": 5, "location_summary": "Duarte, California • Grand Rapids, Michigan • New York, New York + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07700160" } ] }